These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38965463)

  • 1. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.
    Scheffler A; Basten J; Menzel L; Binz D; Becker WA; Breunung V; Schenk H; Kleinschnitz C; Nsaka M; Lindner D; Holle D
    J Headache Pain; 2024 Jul; 25(1):109. PubMed ID: 38965463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.
    Scheffler A; Wenzel P; Bendig M; Gendolla A; Basten J; Kleinschnitz C; Nsaka M; Lindner D; Naegel S; Burow P; Fleischmann R; Holle D
    J Headache Pain; 2024 May; 25(1):79. PubMed ID: 38755541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Diener HC; Marmura MJ; Tepper SJ; Cowan R; Starling AJ; Diamond ML; Hirman J; Mehta L; Brevig T; Sperling B; Cady R
    Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
    Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
    Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
    Curone M; Tullo V; Didier HA; Bussone G
    Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine.
    Driessen MT; Cohen JM; Thompson SF; Patterson-Lomba O; Seminerio MJ; Carr K; Totev TI; Sun R; Yim E; Mu F; Ayyagari R
    J Headache Pain; 2022 May; 23(1):56. PubMed ID: 35578182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies targeting CGRP signaling for medication overuse headache.
    Koumprentziotis IA; Mitsikostas DD
    Curr Opin Neurol; 2022 Jun; 35(3):353-359. PubMed ID: 35674079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.
    Storch P; Burow P; Möller B; Kraya T; Heintz S; Politz N; Naegel S
    Acta Neurol Belg; 2022 Aug; 122(4):931-937. PubMed ID: 34406609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience.
    Scheffler A; Schenk H; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Holle D
    J Headache Pain; 2021 Sep; 22(1):111. PubMed ID: 34544359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.
    Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D
    Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Marmura MJ; Diener HC; Cowan RP; Tepper SJ; Diamond ML; Starling AJ; Hirman J; Mehta L; Brevig T; Cady R
    Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
    Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transition of medication overuse status by acute medication categories in episodic or chronic migraine patients to non-overuse status after receiving anti-CGRP monoclonal antibodies: a systematic review and meta-analysis of phase 3 randomized control trial.
    Sirilertmekasakul C; Panto A; Lekhalawan P; Panyarachun P; Jindasakchai P; Rattanawong W
    Neurol Sci; 2024 Apr; ():. PubMed ID: 38564060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F; Brunelli N; Messina R; Costa CM; Colombo B; Torelli P; Quintana S; Cevoli S; Favoni V; d'Onofrio F; Egeo G; Rao R; Filippi M; Barbanti P; Altamura C
    J Headache Pain; 2021 Dec; 22(1):154. PubMed ID: 34922444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of medication overuse and medication overuse headache in patients with migraine: a randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application.
    Diener HC; Donoghue S; Gaul C; Holle-Lee D; Jöckel KH; Mian A; Schröder B; Kühl T
    Trials; 2022 May; 23(1):382. PubMed ID: 35546412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.
    Guerzoni S; Baraldi C; Pensato U; Favoni V; Lo Castro F; Cainazzo MM; Cevoli S; Pani L
    Neurol Sci; 2022 Jun; 43(6):3823-3830. PubMed ID: 35015202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
    BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months.
    Caronna E; Gallardo VJ; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    J Headache Pain; 2021 Oct; 22(1):120. PubMed ID: 34620085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.